B2Gold stock today: BTG flat in premarket as gold slips on year-end profit-taking

B2Gold stock today: BTG flat in premarket as gold slips on year-end profit-taking

NEW YORK, December 31, 2025, 08:58 ET — Premarket

  • B2Gold shares were little changed in premarket trading ahead of the year’s final U.S. session.
  • Gold eased as traders took profits after a historic 2025 rally and higher futures margin requirements.
  • Investors are watching bullion volatility and the miner’s next quarterly update in early 2026.

B2Gold Corp shares were up about 0.1% at $4.56 in premarket trading on Wednesday, little changed from Tuesday’s close. The gold miner tracked a softer tone in bullion prices into the year-end session.

The timing matters. Gold miners often trade like a leveraged bet on bullion because revenue is tied to the metal price while many operating costs adjust more slowly.

Thin holiday liquidity can make that linkage feel even tighter. Small shifts in gold can translate quickly into equity moves when fewer investors are trading.

Spot gold fell 0.9% to $4,307.56 per ounce by 1219 GMT and U.S. February futures dropped 1.5%, Reuters reported. Independent analyst Ross Norman said gold was seeing “heightened price volatility” as profit-taking hit after the CME raised margin requirements — the cash traders must post to hold futures positions. Gold is still up about 65% this year, its strongest annual gain since 1979, Reuters said. Reuters

B2Gold is headquartered in Vancouver and runs producing mines in Canada, Mali, Namibia and the Philippines, and it pays a quarterly dividend of $0.02 per share, according to its website. B2Gold

In its latest results, B2Gold said third-quarter gold production totaled 254,369 ounces, including “pre-commercial” output at Goose — production booked before a mine is formally declared commercial. The company reiterated 2025 production guidance of 890,000 to 965,000 ounces from the Fekola, Masbate and Otjikoto mines, while cutting Goose Mine guidance to 50,000 to 80,000 ounces. It reported consolidated all-in sustaining costs — a broad cost metric that includes sustaining capital — of $1,479 per gold ounce sold for the quarter. B2Gold

Those costs matter because a miner’s profit margin depends on the spread between its costs and the realized gold price. Sharp swings in bullion can prompt investors to re-price miners quickly, even if mine plans have not changed.

U.S. stock index futures edged lower ahead of the open and trading volumes were set to stay light in the holiday-shortened week, with U.S. markets closed on Thursday. Investors are also watching the Federal Reserve’s rate path into 2026, which tends to influence gold because the metal pays no interest. Reuters

Other miners were also sensitive to bullion moves, with Newmont and Freeport-McMoRan among the premarket decliners as precious metals softened, Barron’s reported. Barron’s

BTG is sitting near the mid-$4 range going into the open. Traders will watch whether the stock can hold that area if bullion selling accelerates, or rebound if gold steadies after this week’s volatility.

The next scheduled company catalyst is B2Gold’s next quarterly report. Nasdaq’s earnings calendar estimates the company will report around Feb. 18, 2026, though the date is not confirmed. Nasdaq

Until then, investors will be looking for any signal on 2026 production and cost guidance, including how Goose ramps up and how royalties and taxes track with higher gold prices. Updates on spending and dividend policy could also steer sentiment.

Stock Market Today

  • CONMED Stock Poised for Growth Amid Broad Product Spectrum, Yet Faces Headwinds
    December 31, 2025, 9:24 AM EST. CONMED Corp CNMD is positioned for growth on a broad product spectrum and a solid recurring revenue base, with fiscal 2025 earnings growth forecast at 19.3%. The company has posted earnings surprises in 3 of the last 4 quarters and trades as a Zacks Rank #3 (Hold); the corporate cap is about $2.26 billion. In General Surgery, CNMD's endo-mechanical instruments and specialty devices have driven demand, with the AirSeal insufflator contributing to near-term topline strength. However, headwinds include supply-chain constraints and data-security risks, plus weather-related disruptions in the U.S. foot-and-ankle market that could temper quarterly results. The portfolio spans orthopedics, laparoscopic, robotics, gastroenterology, and cardiopulmonary products, highlighted by innovations like the Anchor Tissue Retrieval bag and MicroFree platform; the 2022 In2Bones acquisition broadened the orthopedic lineup. Investors should weigh growth potential against operational risks.
Transocean stock today nudges higher in premarket after Australia drilling update
Previous Story

Transocean stock today nudges higher in premarket after Australia drilling update

Applied Digital stock rises premarket as ChronoScale cloud spinout with Ekso draws investor focus
Next Story

Applied Digital stock rises premarket as ChronoScale cloud spinout with Ekso draws investor focus

Go toTop